Working… Menu
Trial record 95 of 143 for:    NIFEDIPINE

Sitaxsentan in Proteinuric Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00817037
Recruitment Status : Unknown
Verified January 2009 by University of Edinburgh.
Recruitment status was:  Active, not recruiting
First Posted : January 6, 2009
Last Update Posted : January 6, 2009
Encysive Pharmaceuticals
Information provided by:
University of Edinburgh

Brief Summary:

Patients with chronic kidney disease (CKD) have higher blood pressures than the general population. They also tend to have protein leaking into the urine (proteinuria). CKD, high blood pressure and proteinuria independently and together increase the risk of developing atherosclerosis (hardening) of the arteries that leads to diseases such as heart attack and stroke. Although there are a number of drugs available that lower blood pressure, these are not always fully effective. Furthermore, there are even fewer drugs that simultaneously lower blood pressure, reduce proteinuria, and slow down kidney damage in CKD.

Recent research has shown that drugs like sitaxsentan not only lower blood pressure but also reduce proteinuria and potentially slow down the progression of CKD [1,2]. Before sitaxsentan can become freely available to individuals with CKD it is important to look at the effects this drug could have on proteinuria and blood pressure.

  1. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193.
  2. Krum H, Viskoper RJ, Lacourciere Y et al. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Engl J Med 1998;338:784-790.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Proteinuria Blood Pressure Drug: Sitaxsentan Drug: Nifedipine Drug: Placebo tablet Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Sitaxsentan Once Daily Dosing on Proteinuria, 24-Hour Systemic Blood Pressure, and Arterial Stiffness in Subjects With Chronic Kidney Disease
Study Start Date : May 2007
Estimated Primary Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
Drug Information available for: Nifedipine

Arm Intervention/treatment
Experimental: Sitaxsentan

Once daily oral sitaxsentan 100mg given over a period of 6 weeks.

24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment

Drug: Sitaxsentan
Sitaxsentan 100mg once daily oral dosing for 6 weeks
Other Name: Thelin

Placebo Comparator: Placebo

Once daily oral placebo tablet given over a period of 6 weeks.

24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment

Drug: Placebo tablet
Placebo tablet once daily oral dosing for 6 weeks

Active Comparator: Nifedipine

Open labeled active comparator

Once daily oral nifedipine 30mg given over a period of 6 weeks.

24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment

Drug: Nifedipine
Nifedipine 30mg once daily oral dosing for 6 weeks
Other Name: Adalat LA

Primary Outcome Measures :
  1. The principal objective of this study is to evaluate whether sitaxsentan reduces proteinuria in people with chronic kidney disease. [ Time Frame: 6 Weeks ]

Secondary Outcome Measures :
  1. Secondary objective of this study is to evaluate whether sitaxsentan reduces systemic blood pressure in people with chronic kidney disease. [ Time Frame: 6 weeks ]
  2. Secondary objective is to determine whether sitaxsentan improves indices of arterial stiffness in people with chronic kidney disease [ Time Frame: 6 weeks ]
  3. Secondary objectives is to determine the safety of sitaxsentan in chronic kidney disease [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Has Stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (using the Cockcroft and Gault equation for calculation of glomerular filtration rate) with proteinuria, including any of the following aetiologies: immunoglobulin A (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy.
  2. Is between 18 and 70 years of age, inclusive.
  3. Has a body mass index (BMI) between 18 and 35 kg/m2, inclusive.
  4. Is willing and able to adhere to the protocol requirements.
  5. Provides written informed consent before any study procedure is performed.

Exclusion Criteria:

  1. Requires peritoneal dialysis or haemodialysis.
  2. Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.
  3. Has a serum albumin in the nephrotic range (< 30 g/L) during Screening.
  4. Has a sustained sitting systolic blood pressure (BP) > 160 mmHg or sustained sitting diastolic BP > 100 mmHg during Screening.
  5. Has postural hypotension during Screening, which is defined as a decrease in systolic BP ≥ 20 mmHg and/or a decrease in diastolic BP ≥ 10 mmHg, comparing sitting and standing measurements.
  6. Has a history and/or evidence of ischaemic heart disease.
  7. Has or had a malignancy, with the exception of adequately-treated basal cell or squamous cell carcinoma of the skin, that required significant medical intervention within the past 3 months and/or is likely to result in death within the next 2 years.
  8. Has a history of allergies or hypersensitivity to sitaxsentan or nifedipine or the excipients of either drug.
  9. Has a clinically significant psychiatric, addictive, neurological disease or any other condition that, in the Investigator's opinion, would compromise his/her ability to give informed consent, participate fully in this study, prevent adherence to the requirements of the study protocol, or would compromise the interpretation of the data obtained from this study.
  10. Uses a prohibited medication or plans to use a prohibited medication during the study.

    • Prohibited medications include cyclosporine A, alternative endothelin (ET) receptor antagonists, phosphodiesterase inhibitors, and/or vitamin K antagonists (e.g., warfarin). The intermittent use of phosphodiesterase inhibitors (e.g., sildenafil) "as needed" for erectile dysfunction is acceptable, however, as long as the subject is not dosed within 24 hours of an efficacy assessment.
  11. Received treatment with an investigational drug or device within 30 days prior to study entry.
  12. Has a history of organ transplantation.
  13. Has atrial fibrillation requiring anticoagulation or a history (in the preceding 6 months) of any intermittent cardiac dysrhythmia that may require anticoagulation therapy.
  14. Has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) level > 1.5 × the upper limit of the normal range (ULN) at Screening and/or serum total bilirubin > ULN.
  15. Has a haemoglobin concentration < 8.0 mg/dL at Screening.
  16. Has positive serological results for hepatitis B and/or hepatitis C.
  17. Is a woman of childbearing potential who is unwilling to use 2 forms of contraceptive therapy, including at least 1 barrier method, throughout the study. (Women who are surgically sterile or who are post-menopausal for at least 2 years are not considered to be of childbearing potential.)
  18. Is pregnant, lactating, or breastfeeding.
  19. Has, in the opinion of the Investigator, a dependence on alcohol.
  20. Has, in the opinion of the Investigator, a dependence on illicit drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00817037

Layout table for location information
United Kingdom
Clinical Research Centre, Western General Hospital
Edinburgh, Scotland, United Kingdom, EH4 2XU
Sponsors and Collaborators
University of Edinburgh
Encysive Pharmaceuticals
Layout table for investigator information
Study Director: David Webb, MD DSc FRCP FRSE FMedSci University of Edinburgh
Principal Investigator: Neeraj Dhaun, MBChB University of Edinburgh

Layout table for additonal information
Responsible Party: Professor David Webb MD DSc FRCP FRSE FMedSci, University of Edinburgh Identifier: NCT00817037     History of Changes
Other Study ID Numbers: 2007/W/CRC/02
CTA# 2006-002004-33
First Posted: January 6, 2009    Key Record Dates
Last Update Posted: January 6, 2009
Last Verified: January 2009
Keywords provided by University of Edinburgh:
Chronic kidney disease
Blood pressure
Arterial stiffness
Endothelin antagonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Urination Disorders
Urological Manifestations
Signs and Symptoms
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Endothelin Receptor Antagonists